Home

Moderna, Inc. - Common Stock (MRNA)

24.49
-0.12 (-0.49%)
NASDAQ · Last Trade: Sep 28th, 5:57 AM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close24.61
Open24.51
Bid24.50
Ask24.54
Day's Range23.91 - 24.78
52 Week Range23.15 - 67.96
Volume10,244,412
Market Cap9.53B
PE Ratio (TTM)-3.252
EPS (TTM)-7.5
Dividend & YieldN/A (N/A)
1 Month Average Volume12,463,799

Chart

About Moderna, Inc. - Common Stock (MRNA)

Moderna Inc is a biotechnology company focused on developing innovative messenger RNA (mRNA) therapeutics and vaccines for a wide array of diseases. Utilizing its proprietary mRNA technology platform, Moderna aims to harness the body's own cellular machinery to produce proteins that can help prevent or treat illnesses, including infectious diseases, cancer, and rare genetic disorders. The company gained significant attention for its development of an effective COVID-19 vaccine, but its pipeline also includes various other candidates in different stages of clinical development aimed at addressing unmet medical needs. Through its research and development efforts, Moderna seeks to transform the field of medicine and improve patient outcomes globally. Read More

News & Press Releases

Stay informed with the top movers within the S&P500 index on Friday.chartmill.com
Curious about the top performers within the S&P500 index one hour before the close of the markets on Friday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Via Chartmill · September 26, 2025
Pharma Tariffs Back In Spotlight On New Trump Threatinvestors.com
President Donald Trump threatened 100% tariffs on some drug imports.
Via Investor's Business Daily · September 26, 2025
These S&P500 stocks are moving in today's sessionchartmill.com
Curious about the S&P500 stocks that are in motion on Friday? Join us as we explore the top movers within the S&P500 index during today's session.
Via Chartmill · September 26, 2025
Moderna Says Updated mNEXSPIKE Covid Shot Demonstrated Robust Immune Response In Studystocktwits.com
Via Stocktwits · September 23, 2025
Is Moderna Gaining or Losing Market Support?benzinga.com
Via Benzinga · September 22, 2025
Gapping S&P500 stocks in Friday's sessionchartmill.com
Wondering which stocks are making significant price gaps? Explore the S&P500 index on Friday to find the gap up and gap down stocks in today's session.
Via Chartmill · September 26, 2025
Robert F. Kennedy Jr. Faces Impeachment Push From Haley Stevens Over 'Health Care Chaos' And Rising Costs: 'Enough Is Enough'benzinga.com
Rep. Haley Stevens (D-Mich.) announced that she will introduce articles of impeachment against Health and Human Services Secretary Robert F. Kennedy Jr.
Via Benzinga · September 26, 2025
Stay informed with the top movers within the S&P500 index on Thursday.chartmill.com
Stay updated with the movements of the S&P500 index one hour before the close of the markets on Thursday. Discover which stocks are leading as top gainers and losers in today's session.
Via Chartmill · September 25, 2025
Moderna Stands By UK As Pharma Giants Criticize Pricing, UK Secures First Onshore mRNA Vaccine Production Centrebenzinga.com
Moderna, Inc.‘s (NASDAQ: MRNA) UK chief Darius Hughes defended Britain's drug pricing policies after the country was branded the "worst in Europe."
Via Benzinga · September 25, 2025
Moderna Opens State-of-the-Art Manufacturing and R&D Facility in the UK
The Moderna Innovation and Technology Centre in Harwell, Oxfordshire is now fully operational and Moderna is licensed to supply British-made COVID-19 vaccines to the UK population
Via ACCESS Newswire · September 24, 2025
Flagship Pioneering, Creator Of Moderna, Launches Extuitive With $20M To Reinvent Consumer Products Using AI Shoppersbenzinga.com
Via Benzinga · September 23, 2025
Moderna's COVID-19 Vaccine Update Boosts Antibodies 16-Fold, Data Showsbenzinga.com
Moderna's 2025-2026 mNEXSPIKE showed strong immune response and safety in Phase 4 trials, reinforcing FDA approval for the LP.8.1-targeting formula.
Via Benzinga · September 23, 2025
Stocks making big moves yesterday: Plug Power, Moderna, Magnite, Compass, and RE/MAX
Check out the companies making headlines yesterday:
Via StockStory · September 23, 2025
Moderna Announces mNEXSPIKE Generates Strong Immune Response Against LP.8.1 Variant in Humans
Preliminary analysis showed the 2025-2026 formula of mNEXSPIKE generated greater than a 16-fold increase in LP.8.1-neutralizing antibodies across age groups
Via ACCESS Newswire · September 23, 2025
Trump Advises Parents To Split Vaccines, Delay Hepatitis B Shots Until Age 12: 'This Is Based On What I Feel'benzinga.com
President Donald Trump on Monday offered advice on childhood vaccination schedules, encouraging parents to split up certain immunizations and delay certain others, in sharp contradiction to current medical recommendations.
Via Benzinga · September 22, 2025
Why Moderna (MRNA) Stock Is Trading Up Today
Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 6.1% in the afternoon session after the company announced it delivered the first mRNA vaccines fully manufactured in Canada to the nation's provinces and territories. 
Via StockStory · September 22, 2025
Which S&P500 stocks are moving on Monday?chartmill.com
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Monday.
Via Chartmill · September 22, 2025
Stocks Extend Records, Gold Soars To $3,740: What's Moving Markets Monday?benzinga.com
Wall Street is on track for its third straight day of gains, with major large-cap indices extending records as investors remain optimistic about corporate earnings and upcoming rate cuts.
Via Benzinga · September 22, 2025
Top S&P500 movers in Monday's sessionchartmill.com
Stay informed about the performance of the S&P500 index in the middle of the day on Monday. Uncover the top gainers and losers in today's session for valuable insights.
Via Chartmill · September 22, 2025
3 of Wall Street’s Favorite Stocks with Open Questions
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
Via StockStory · September 22, 2025
CDC Ends Universal Covid Vaccine Recommendation; Moderna Skidsinvestors.com
Moderna stock toppled Friday after advisors to the CDC and Prevention ended the universal recommendation for Covid vaccines.
Via Investor's Business Daily · September 19, 2025
Moderna Announces First Made-in-Canada mRNA Vaccines Delivered to Canadian Provinces and Territories
CAMBRIDGE, MA / ACCESS Newswire / September 19, 2025 / Moderna announced today that the first mRNA vaccines fully manufactured in Canada are being shipped to provinces and territories. This milestone advances Canada's domestic vaccine production capacity and strengthens national health security.
Via ACCESS Newswire · September 19, 2025
Elizabeth Warren Says Measles Can Hit Record Highs, Slams RFK Jr.'s CDC Panel For Delaying Vaccine: 'How Does That Keep Our Kids Safe?'benzinga.com
Sen. Elizabeth Warren (D-Mass.) on Thursday criticized the Centers for Disease Control and Prevention's vaccine advisory panel following its controversial vote to delay the combined measles, mumps, rubella, and varicella or MMRV vaccine for children under 4 years old.
Via Benzinga · September 18, 2025
The Battle Over Covid Vaccines Hits A Fever Pitch As RFK-Picked Panel Makes Its Debutinvestors.com
The reworked ACIP will make its debut Friday when the panelists weigh the suite of new Covid boosters.
Via Investor's Business Daily · September 18, 2025
3 Small-Cap Stocks with Questionable Fundamentals
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.
Via StockStory · September 18, 2025